From Canada to Australia, PreveCeutical Medical received its first international cannabis shipment.
In a show of an increased cross-border movement for the marijuana industry, PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) said recently that it has received its first international cannabis shipment to Australia from the Canadian company, Aurora Cannabis Inc (TSE:ACB).
The Vancouver-based PreveCeutical is developing new cannabis-based medicines and delivery systems through a partnership with researchers in Australia.
PreveCeutical needed to receive the shipment of dried cannabis flower and oils from the Canadian cannabis producer Aurora.
In a press release following the international transaction, PreveCeutical is now able to start testing of soluble gel (Sol-gel) delivery system.
The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.
The international shipment took place in late March after earlier in the same month, PreveCeutical said it had received the key permits to allow this material to be imported into Australia.
It will be used for the group’s research led by Preveceutical’s chief research officer Dr. Harendra Parekh at the University of Queensland.
“Testing of the imported cannabis strains in the application of soluble gel (Sol-gel) drug-delivery technology to cannabinoids is now expected to commence,” said the firm in a brief statement.
“The purpose of the testing will be to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.”